Zimmer Biomet Holdings Past Earnings Performance
Past criteria checks 1/6
Zimmer Biomet Holdings has been growing earnings at an average annual rate of 20%, while the Medical Equipment industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 0.8% per year. Zimmer Biomet Holdings's return on equity is 7.3%, and it has net margins of 11.8%.
Key information
20.0%
Earnings growth rate
20.0%
EPS growth rate
Medical Equipment Industry Growth | 8.9% |
Revenue growth rate | 0.8% |
Return on equity | 7.3% |
Net Margin | 11.8% |
Last Earnings Update | 31 Dec 2024 |
Recent past performance updates
Recent updates
Zimmer Biomet: Adding To The Growth Profile
Feb 07Investors Appear Satisfied With Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) Prospects
Feb 06These 4 Measures Indicate That Zimmer Biomet Holdings (NYSE:ZBH) Is Using Debt Reasonably Well
Jan 10Zimmer Biomet: Back On Offense With Strong Cash Flow Outlook
Jan 05Zimmer Biomet Holdings (NYSE:ZBH) Is Due To Pay A Dividend Of $0.24
Dec 21At US$108, Is It Time To Put Zimmer Biomet Holdings, Inc. (NYSE:ZBH) On Your Watch List?
Dec 08Shareholders Can Be Confident That Zimmer Biomet Holdings' (NYSE:ZBH) Earnings Are High Quality
Nov 07Results: Zimmer Biomet Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Nov 02Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) Share Price Not Quite Adding Up
Oct 03Zimmer Biomet: The Undervalued Titan Of Joint Replacements
Oct 02Zimmer Biomet Stock: Don't Jump In At The 52-Week Low
Sep 19We Like These Underlying Return On Capital Trends At Zimmer Biomet Holdings (NYSE:ZBH)
Sep 18Zimmer Biomet Holdings (NYSE:ZBH) Is Due To Pay A Dividend Of $0.24
Sep 02Zimmer Biomet Holdings (NYSE:ZBH) Seems To Use Debt Quite Sensibly
Aug 27Are Investors Undervaluing Zimmer Biomet Holdings, Inc. (NYSE:ZBH) By 45%?
Jul 15Investors Interested In Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) Earnings
Jul 02Zimmer Biomet: Brighter Prospects In H2 2024
Jul 02Zimmer Biomet Holdings (NYSE:ZBH) Has Affirmed Its Dividend Of $0.24
Jun 19When Should You Buy Zimmer Biomet Holdings, Inc. (NYSE:ZBH)?
Jun 05Zimmer Biomet Holdings' (NYSE:ZBH) Dividend Will Be $0.24
May 21Zimmer Biomet Holdings: Moving Along
May 17The Return Trends At Zimmer Biomet Holdings (NYSE:ZBH) Look Promising
May 02Is Zimmer Biomet Holdings (NYSE:ZBH) Using Too Much Debt?
Mar 20Zimmer Biomet Holdings (NYSE:ZBH) Will Pay A Dividend Of $0.24
Mar 02Zimmer Biomet: Weight Loss Drug Concerns Are Overblown
Feb 05Zimmer Biomet: Growth Acceleration Is Likely Driven By ROSA; Initiate With 'Buy'
Jan 20Zimmer Biomet Holdings: Visible Growth Drivers And Strong Execution
Dec 18Zimmer Biomet: Still Many Questions After A Solid Year So Far
Nov 26Zimmer Biomet Holdings: Growth Strategies For 2023 Instill Confidence
Sep 14Revenue & Expenses Breakdown
How Zimmer Biomet Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 24 | 7,679 | 904 | 2,902 | 437 |
30 Sep 24 | 7,596 | 1,084 | 2,856 | 442 |
30 Jun 24 | 7,525 | 997 | 2,822 | 448 |
31 Mar 24 | 7,452 | 964 | 2,816 | 456 |
31 Dec 23 | 7,394 | 1,024 | 2,793 | 459 |
30 Sep 23 | 7,279 | 474 | 2,768 | 453 |
30 Jun 23 | 7,196 | 506 | 2,757 | 438 |
31 Mar 23 | 7,108 | 450 | 2,727 | 420 |
31 Dec 22 | 6,940 | 290 | 2,668 | 406 |
30 Sep 22 | 6,892 | 366 | 2,649 | 394 |
30 Jun 22 | 6,908 | 334 | 2,632 | 386 |
31 Mar 22 | 6,889 | 325 | 2,631 | 452 |
31 Dec 21 | 6,827 | 445 | 2,626 | 436 |
30 Sep 21 | 7,135 | 834 | 2,787 | 440 |
30 Jun 21 | 7,379 | 914 | 2,915 | 432 |
31 Mar 21 | 6,842 | 563 | 2,886 | 355 |
31 Dec 20 | 6,128 | -11 | 2,524 | 323 |
30 Sep 20 | 7,065 | -152 | 3,030 | 393 |
30 Jun 20 | 7,028 | 37 | 3,042 | 422 |
31 Mar 20 | 7,791 | 377 | 3,221 | 446 |
31 Dec 19 | 7,982 | 1,132 | 3,279 | 449 |
30 Sep 19 | 7,928 | -90 | 3,331 | 429 |
30 Jun 19 | 7,872 | -359 | 3,299 | 411 |
31 Mar 19 | 7,891 | -308 | 3,268 | 398 |
31 Dec 18 | 7,933 | -379 | 3,372 | 392 |
30 Sep 18 | 7,930 | 1,753 | 3,119 | 386 |
30 Jun 18 | 7,907 | 1,690 | 3,071 | 381 |
31 Mar 18 | 7,849 | 1,689 | 3,029 | 375 |
31 Dec 17 | 7,803 | 1,814 | 3,096 | 370 |
30 Sep 17 | 7,748 | 652 | 2,988 | 371 |
30 Jun 17 | 7,768 | 712 | 3,012 | 375 |
31 Mar 17 | 7,752 | 497 | 2,972 | 371 |
31 Dec 16 | 7,668 | 306 | 2,906 | 366 |
30 Sep 16 | 7,604 | 363 | 2,900 | 356 |
30 Jun 16 | 7,534 | 227 | 2,865 | 344 |
31 Mar 16 | 6,767 | 84 | 2,577 | 306 |
31 Dec 15 | 5,998 | 147 | 2,284 | 269 |
30 Sep 15 | 5,287 | 174 | 2,000 | 229 |
30 Jun 15 | 4,631 | 325 | 1,730 | 192 |
31 Mar 15 | 4,646 | 670 | 1,730 | 188 |
31 Dec 14 | 4,673 | 720 | 1,751 | 187 |
30 Sep 14 | 4,691 | 802 | 1,789 | 188 |
30 Jun 14 | 4,659 | 784 | 1,804 | 191 |
31 Mar 14 | 4,646 | 764 | 1,818 | 198 |
Quality Earnings: ZBH has a large one-off loss of $289.2M impacting its last 12 months of financial results to 31st December, 2024.
Growing Profit Margin: ZBH's current net profit margins (11.8%) are lower than last year (13.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ZBH's earnings have grown by 20% per year over the past 5 years.
Accelerating Growth: ZBH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ZBH had negative earnings growth (-11.7%) over the past year, making it difficult to compare to the Medical Equipment industry average (11.9%).
Return on Equity
High ROE: ZBH's Return on Equity (7.3%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/18 08:11 |
End of Day Share Price | 2025/02/18 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zimmer Biomet Holdings, Inc. is covered by 63 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
David Toung | Argus Research Company |
Stephan Gasteyger | Atlantic Equities LLP |
Jeffrey Johnson | Baird |